Cargando…

Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1

Etravirine is an oral diarylpyrimidine compound, a second-generation human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) with expanded antiviral activity against NNRTI-resistant HIV-1, to be used in combination therapy for treatment-experienced patients...

Descripción completa

Detalles Bibliográficos
Autor principal:	Viani, Rolando M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218688/ https://www.ncbi.nlm.nih.gov/pubmed/22096392

Ejemplares similares

The role of etravirine in the management of treatment-experienced pediatric patients with HIV
por: Osterholzer, Danielle
Publicado: (2013)

Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea
por: Kwon, Oh-Kyung, et al.
Publicado: (2015)

Profile of etravirine for the treatment of HIV infection
por: Tseng, Alice, et al.
Publicado: (2010)

Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age
por: MacBrayne, Christine E., et al.
Publicado: (2021)

Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand
por: Lyons, Alex, et al.
Publicado: (2022)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection
por: Rosso, R, et al.
Publicado: (2009)

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
por: Kakuda, Thomas, et al.
Publicado: (2012)

Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection
por: Stellbrink, Hans-Jürgen
Publicado: (2010)

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
por: Orrell, Catherine, et al.
Publicado: (2015)

Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial)
por: Charpentier, Charlotte, et al.
Publicado: (2013)

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
por: Mulligan, Nikki, et al.
Publicado: (2016)

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial
por: Arathoon, Eduardo, et al.
Publicado: (2017)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Decreased Phenotypic Susceptibility to Etravirine in Patients with Predicted Genotypic Sensitivity
por: Agneskog, Eva, et al.
Publicado: (2014)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Inflammasomes in Human Immunodeficiency Virus Type 1 Infection
por: Wang, Qiankun, et al.
Publicado: (2022)

Experimental data of co-crystals of Etravirine and L-tartaric acid
por: Rekdal, Mikal, et al.
Publicado: (2017)

Repositioning of Etravirine as a Potential CK1ε Inhibitor by Virtual Screening
por: Córdova-Bahena, Luis, et al.
Publicado: (2021)

Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network
por: Gebo, Kelly, et al.
Publicado: (2013)

Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials
por: Nelson, Mark, et al.
Publicado: (2014)

Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients
por: Patel, Dishank, et al.
Publicado: (2013)

A study of antiretroviral resistance patterns in treatment experienced and naive human immunodeficiency virus infected-patients
por: Harjani, Raj, et al.
Publicado: (2016)

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study
por: Rockstroh, Jürgen K, et al.
Publicado: (2018)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
por: Tyrer, M, et al.
Publicado: (2010)

Targeting Human Immunodeficiency Virus Type 1 Assembly, Maturation and Budding
por: Wapling, Johanna, et al.
Publicado: (2007)

Eradication of Human Immunodeficiency Virus Type-1 (HIV-1)-Infected Cells
por: Düzgüneş, Nejat, et al.
Publicado: (2019)

Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapy–Experienced Ugandans With Virologic Failure
por: Mpoza, Edward, et al.
Publicado: (2019)

Human Immunodeficiency Virus Type 2: The Neglected Threat
por: Ceccarelli, Giancarlo, et al.
Publicado: (2021)

Putative roles of purinergic signaling in human immunodeficiency virus-1 infection
por: Pacheco, Paulo AF, et al.
Publicado: (2014)

Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
por: Poveda, Eva, et al.
Publicado: (2010)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
por: Tommasi, Chiara, et al.
Publicado: (2011)

Development of a practical synthesis of etravirine via a microwave-promoted amination
por: Feng, Da, et al.
Publicado: (2018)

Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort
por: Allavena, Clotilde, et al.
Publicado: (2014)

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
por: Neely, Michael, et al.
Publicado: (2009)

Innate Immune Evasion Strategies by Human Immunodeficiency Virus Type 1
por: Guha, Debjani, et al.
Publicado: (2013)

Induction of Autophagy to Achieve a Human Immunodeficiency Virus Type 1 Cure
por: Campbell, Grant R., et al.
Publicado: (2021)

Escape from Human Immunodeficiency Virus Type 1 (HIV-1) Entry Inhibitors
por: De Feo, Christopher J., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4g6hhc42tso8mu1ba3iq7scc7i